Certara Software Revenue Jumps 11% as Services Decline

Certara Inc. (CERT) reported Q3 2026 software revenue growth of 11% to $48.8M, while services revenue declined 2% to $46.1M. Total revenue rose 4% to $94.9M, and net loss narrowed to $3.6M. Adjusted EBITDA increased 6% to $30.2M. The company maintained its full-year revenue growth forecast of 2-3% and updated its adjusted earnings outlook to 31-34 cents per share.

Original reporting
Published Nov 11, 2026, 3:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 6:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Certara Software Revenue Jumps 11% as Services Decline — source image
Decision brief

The 30-second read

$CERTBearishHigh
01

Why it matters

The earnings release provides fresh guidance that narrows growth expectations, which may lead to short‑term price pressure despite strong software performance.

02

Market read

First‑time earnings release with new guidance for a mid‑cap biotech software company; relevant for traders monitoring earnings and guidance updates.

03

What to watch

The appointment of a new chief product officer may accelerate product rollout, and cash balance of $215 M provides runway for strategic investments.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

Certara Inc. reported its Q1 2026 results, highlighting double‑digit software revenue growth and a narrowed full‑year revenue outlook.

Company-level read

Ticker impact

$CERTBearishHigh confidence
Context

Q1 2026 earnings released with 11% software revenue growth and narrowed full‑year revenue guidance to 2‑3% growth.

Expected impact

likely pressure as the market prices in the lower full‑year revenue outlook

Evidence & confidence

The company trimmed its full‑year revenue growth forecast while reporting solid software growth, creating mixed signals that typically weigh on the share price.

Market effects

Software‑focused drug‑development tools may see relative strength versus services peers.

U.S. biotech and pharma software segment could be modestly affected.

Limited to investors tracking mid‑cap biotech software companies.

Counterpoint

Software growth could accelerate faster than guidance suggests, offering upside if the market overreacts to the modest outlook.

Key entities

  • Certara Inc.

    Drug‑development technology firm reporting Q1 results.

  • Jon Resnick

    CEO who commented on software momentum.

  • Grant Peterson

    New chief product officer hired to drive software development.

Related articles

$CERTMedAI 8/10

An Idle Mill and Old Open Pits Draw a New Plan in Southern Argentina

Cerrado Gold Inc. (TSX.V: CERT) (OTCQX: CRDOF) acquired a past-producing mine in Argentina for $20M, aiming to restart operations by 2027. The mine previously produced 1.4M gold equivalent ounces, with peak output of 137,500 ounces in 2011. The company plans a $40,000m drill program for a resource estimate, funded by its existing Santa Cruz operation.

$CERTMed

Why Did Certara (CERT) Shares Climb After Its Latest Update?

Certara (CERT) reported Q3 2026 revenue of $94.9M, up from $90.89M a year earlier, with net income of $5.59M. However, nine-month revenue of $282.26M showed a net loss of $58.44M. Shares rose 9.83% in one day and 35.94% in 30 days, with a year-to-date return of 39.36%. The company's fair value is estimated at $8.71, suggesting a 40% overvaluation. Certara's AI-driven platforms and acquisitions aim to boost revenue and margins.

$CERTMed

Certara Inc (CERT) Q3 2026 Earnings Call Highlights: Software Growth Accelerates as Margins Expand

Certara Inc (CERT) reported Q3 2026 earnings with software revenue growth of 11% but services revenue declined 2% YoY to $46.1M. Full-year 2026 revenue growth guidance was narrowed to 2%-3%. CEO Jon Resnick highlighted cost savings exceeding $12M and strong software demand across customer tiers. The company is transitioning to a cloud-based model and investing in AI initiatives, expecting growth in 2027. GAAP net loss was $3.6M, and adjusted EPS remained flat at $0.09 YoY.

$CERTMed

Certara, Inc. Q3 2026 Earnings Call Summary

Certara reported 11% organic software revenue growth in Q3 2026, its first double-digit increase in two years. The company divested its Regulatory and Medical Writing business to focus on high-growth areas and reorganized operations. Management expects 2%-3% full-year revenue growth, with software outperforming services. AI capabilities and APAC market expansion are seen as growth drivers for 2027.

$CERTHighAI 8/10

Certara Q3 Earnings Call Highlights

Certara reported Q3 bookings up 4% to $92.5M, with a net loss of $3.6M. The company is accelerating cloud conversions and AI integration, expecting growth impacts in 2027. It narrowed FY2026 revenue growth outlook to 2-3% and updated adjusted earnings outlook to $0.31-$0.34 per share. Certara has $214.9M in cash and $100M available under its revolving credit facility.